Allakos is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. Our initial clinical focus is eosinophilic gastritis and/or eosinophilic duodenitis (previously referred to as eosinophilic gastroenteritis), inflammatory diseases of the gastrointestinal tract. We are also conducting clinical trials for other mast cell and eosinophil driven diseases including chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.